Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

By B. Lehmann, Joshua A. Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol. Journal of Clinical Investigation, 2011

4,973 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/89eb954c789b583c9d949e163097ff18442011fa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, background): “On gene expression profiling, TNBCs can be subdivided into six subtypes: basal-like (BL1 and BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR), as well as an unspecified group (UNS) [166,167].”
NEW STRATEGIES FOR TRIPLE NEGATIVE BREAST CANCER – DECIPHERING THE HETEROGENEITY (2014, methodology): “TNBC cases were identified as previously described (8).”
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge (2019, background): “This leads to deficiencies in DNA damage repair, thus making these tumors more susceptible to DNA damaging agents [146].”
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (2016, methodology): “The TNBC587 dataset represents gene expression from 587 TNBC tumors extracted from 21 publically available Affymetrix microarray datasets and renormalized with each other as previously described[15,21].”
Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping (2017, background): “For example, Birnbaum et al. grouped 27 breast cancer cell lines into luminal, basal and mesenchymal subtypes [7]; Riaz et al. characterized 5 subtypes, i. e. , luminal, luminal-HER2+, ER-negative-HER2+, basal, normal-like, among 51 breast cancer cell lines using a panel of 496 genes identified by P”
Triple-negative breast cancer molecular subtyping and treatment progress (2020, background): “[13], we speculate that the use of growth factor inhibitors in BL-2, M, and MSL subtypes combined with other downstream signal transduction inhibitors (PI3K, MAPK, and Scr inhibitors) might achieve better results.”
Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients (2014, neutral): “Overall, the EMT status is unlikely to be the sole prognostic factor for survival where the composition of histotype or molecular subtype may play a role; this suggests the requirement for stratification of cancers in addition to deciphering the EMT status.”
Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, neutral): “expression patterns [26].”
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer (2013, background): “We hypothesized that the absence of basal-like breast cancer IHC markers would predict for response to antiandrogen therapy as this AR-dependent subtype of breast cancer is distinct from the basal-like subtypes (BL1 and BL2) described by Lehmann and colleagues (6).”
Recent advances in therapeutic strategies for triple-negative breast cancer (2022, methodology): “Initially, six clusters were distinguished from 21 breast cancer datasets by Lehmann in 2011 [5].”
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, background): “Preclinical studies also show heterogeneity of response to other agents in cell lines of the different triple-negative subtypes [52], though this subclassification is not yet ready for clinical application.”